Capgemini
keyboard_backspaceBack to Home
Contact
147 Quai du Président Roosevelt
92130 Issy-les-Moulineaux
France
Head of Industry Life Science
About us
Capgemini, a partner in the business and technological transformation of its clients, supports them in their transition towards a more digital and sustainable world, while creating a positive impact for the society. The Group is responsible and multicultural, with 340,000 employees in more than 50 countries. For more than 55 years, its customers have trusted Capgemini to meet all their needs through technology. Capgemini offers end-to-end services and solutions, from strategy and design to engineering, leveraging its industry-leading AI, cloud, and data capabilities, as well as its industry expertise and partner ecosystem. The Group generated sales of €22.5 billion in 2023.
Business offer
Committed for more than 35 years to major players in the health sector as a partner throughout the value chain from R&D to market launch, our experts in engineering, technology, IT, data and consulting develop innovative human-centered solutions and meet the industrial challenges of the bioproduction sector: Innovation, industrialization, scalability, sustainability:
- Measuring and reducing the environmental impact of production processes
- Optimizing the supply chain Accelerating the digital transformation of the sector thanks to technologies: AI, digital twins, etc.
- Shorten time-to-market
Capgemini has been involved in this sector as a founding member of France Biolead since the launch of the association in December 2022.
By embedding intelligence into products, operations and services, we are supporting the transformation of the industry to the next generation of healthcare and helping to make these biomedicines accessible to patients.
Activities
- Service
- Training Center
- Pre-industrial demonstrator
- Target selection & validation
- Gene / protein discovery
- bioinformatics design
- Assay development in in-vitro & in-vivo models
- Research exploratory companion biomarkers
- Preclinical biomarkers
- Mechanism/Function
- Mechanism of action
- Safety
- PK/PD features
- Indication Identification
- Exploratory toxicology
- Drug-Target interaction
- Level of response duration
- Specificity
- Surrogate markers
- Research exploratory Companion biomarkers
- Bioinformatics design
- Bioinformatics prediction & analysis
- Animal biomarkers
- Human biomarkers
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Risk/benefit profile
- Disease progression / follow-up
- CMC
- GLP compliance
- GLP compliance
- Bioproduction
- Pilot Batches
- Tests
- Optimization
- Scale-Up process
- Process optimization & validation
- DSP (Recovery)
- Fill & Finish
- Batch release
- Storage matter
- Instruction
- Logistic
- Quality assurance, quality control & analytical process
- Stability Assessment
- Cell line analytical development
- Biosafety & Bioanalysis
- Bioproduction analytical test
- Batch release test
- Post-production test
- Real-time stability test
- Formulation
- Formulation
- Storage stability
- Delivery
- Clinical trials
- Phase I
- Phase II
- Phase III
- Phase IV
- Clinical biomarkers
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Risk/benefit profile
- Safety
- Surrogate markers
- Regulatory filing
- Regulatory Filing
- Post-market surveillance
- Post-Market Surveillance
- CMC/analytical quality assessment, quality control
- Cleaning
- Cross contamination
- Sterility
- Deviations
- Contaminants detection
- Safety for gene-edited cells
- Bioproduction engineering
- Cell Expansion
- Scale-Up
- Bioproduction modeling
- Metabolic / Kinetic modeling
- Control / command
- Global optimization
- Economic analyses
- Artificial Intelligence tools
- Delivery
- Supply chain logistics
- Tracking process
- Monitoring logistics
- Bioproduction/CMC/Analytical Quality Assessment, Quality Control
- Supply chain logistics
- Deviations
- Antigen identification, selection, optimization, and validation
- Omics analysis
- Regulatory safety
- Specificity
- Human sequence homologies
- Regulatory safety tests
- Clinical trials
- Phase I
- Phase II (human challenge trials)
- Phase III (large population pending pathogen prevalence)
- Data management
- Vaccine shipment and distribution
- Storage matter
- Cold chain logistics
- Regulatory Filing
- Regulatory Filing
- Post-market surveillance
- Clinical Trial phase IV
